PROBE

First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with and without brain involvement.

Acronym:

PROBE

ACTRN/NCT /ethics:

NCT04543188

Scientific title:

A two-part, phase 1a/b, open-label, multicenter trial evaluating pharmacokinetics, safety and efficacy of pf 07284890 (arry 461) in participants with braf v600 mutant solid tumors with and without brain involvement

Sponsor / Cooperative group:

Pfizer